Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.12
+0.13 (1.00%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
493.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| Puma Biotechnology | 231.24M |
| REGENXBIO | 174.48M |
| Autolus Therapeutics | 117.39M |
| Assembly Biosciences | 74.85M |
| Ovid Therapeutics | 1.58M |
| YD Bio | 1.24M |
| ProKidney | 818.00K |
CTNM News
- 3 days ago - Jones sees greater room for Contineum’s PIPE-791 to differentiate - TheFly
- 4 days ago - Contineum Therapeutics Inc trading resumes - TheFly
- 4 days ago - Contineum Therapeutics Inc trading halted, volatility trading pause - TheFly
- 6 days ago - Contineum price target lowered to $17 from $18 at Morgan Stanley - TheFly
- 9 days ago - Contineum resumed at Early-Stage Biotech at Goldman Sachs - TheFly
- 18 days ago - Contineum Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 18 days ago - Contineum price target lowered to $24 from $26 at Jones - TheFly
- 18 days ago - Contineum price target lowered to $19 from $20 at Baird - TheFly